alendronate has been researched along with methylprednisolone in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Simmons, DJ; Wimalawansa, SJ | 1 |
| Egan, RW; Hey, JA; McHugh, NA; Vercesi, HM | 1 |
| Asadi, F; Rassouli, A; Rezaian, M; Shomali, T | 1 |
| Altavilla, D; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F | 1 |
| Bargagli, E; Bertelli, P; Gonnelli, S; Olivieri, C; Penza, F; Rottoli, P; Volterrani, L | 1 |
| Cai, DH; Chen, H; Deng, WM; He, L; Li, QN; Sun, P; Yang, L | 1 |
| Borowska, A; Dec, R; Gasińska, T; Wichary, H | 1 |
| Li, Q; Li, Y; Meng, Y; Shi, D; Zhang, H; Zhao, J; Zuo, L | 1 |
| Alaeddini, M; Dehpour, AR; Doustimotlagh, AH; Eskandarynasab, M; Etemad-Moghadam, S; Goudarzi, R; Partoazar, A; Takzaree, N | 1 |
| Bitto, A; Booz, C; D'Angelo, T; Giorgi, DA; Ieni, A; Irrera, N; Mannino, F; Mazziotti, S; Pallio, G; Pirrotta, I; Scarfone, A; Squadrito, F | 1 |
2 review(s) available for alendronate and methylprednisolone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Rare localizations of bone sarcoidosis: two case reports and review of the literature.
Topics: Alendronate; Bone Diseases; Bone Neoplasms; Diagnosis, Differential; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Methotrexate; Methylprednisolone; Middle Aged; Osteolysis; Radiography; Rare Diseases; Ribs; Sarcoidosis; Skull; Spine; Treatment Outcome | 2011 |
1 trial(s) available for alendronate and methylprednisolone
| Article | Year |
|---|---|
Effect of methylprednisolone pulse therapy with and without alendronate on biochemical markers of bone turnover in patients with Graves' ophthalmopathy.
Topics: Absorptiometry, Photon; Adult; Alendronate; Anti-Inflammatory Agents; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Combined Modality Therapy; Female; Graves Ophthalmopathy; Humans; Male; Methylprednisolone; Middle Aged; Pulse Therapy, Drug | 2012 |
10 other study(ies) available for alendronate and methylprednisolone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Prevention of corticosteroid-induced bone loss with alendronate.
Topics: Adrenal Cortex Hormones; Alendronate; Animals; Bone Density; Estradiol; Estrogens; Female; Femur; Male; Methylprednisolone; Osteocalcin; Osteoporosis; Ovariectomy; Prednisolone; Rats; Rats, Sprague-Dawley; Testosterone | 1998 |
In vivo rat assay: bone remodeling and steroid effects on juvenile bone by pQCT quantification in 7 days.
Topics: Aging; Alendronate; Animals; Bone and Bones; Bone Density; Bone Development; Bone Remodeling; Dose-Response Relationship, Drug; Femur; Glucocorticoids; Male; Methylprednisolone; Organ Size; Rats; Rats, Sprague-Dawley; Steroids; Tomography, X-Ray Computed | 2003 |
Effect of eicosapentaenoic acid on bone changes due to methylprednisolone in rats.
Topics: Alendronate; Animals; Biomarkers; Body Weight; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Femur; Glucocorticoids; Injections, Subcutaneous; Male; Methylprednisolone; Osteogenesis; Random Allocation; Rats; Rats, Wistar; Tibia | 2009 |
Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcification, Physiologic; Collagen Type I; Disease Models, Animal; Female; Femoral Fractures; Femur; Genistein; Injections, Subcutaneous; Methylprednisolone; Osteoporosis; Peptides; Rats; Rats, Sprague-Dawley; Time Factors | 2009 |
Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats.
Topics: Absorptiometry, Photon; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Glucocorticoids; Male; Methylprednisolone; Organometallic Compounds; Rats; Rats, Sprague-Dawley; Thiophenes | 2010 |
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.
Topics: Alendronate; Animals; Blood Glucose; Body Weight; Bone Density; Female; Femur; Glucocorticoids; Lipids; Lumbar Vertebrae; Metformin; Methylprednisolone; Osteocalcin; Osteoporosis; Protective Agents; Rats, Sprague-Dawley; Tartrate-Resistant Acid Phosphatase | 2019 |
Phosphatidylserine nanoliposomes inhibit glucocorticoid-induced osteoporosis: A potential combination therapy with alendronate.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Femur; Liposomes; Male; Methylprednisolone; Osteocalcin; Osteoclasts; Osteoporosis; Phosphatidylserines; Rats; Rats, Wistar | 2020 |
The Nutraceutical Genistein-Lycopene Combination Improves Bone Damage Induced by Glucocorticoids by Stimulating the Osteoblast Formation Process.
Topics: Alendronate; Animals; Antioxidants; beta Catenin; Bone Density; Core Binding Factor Alpha 1 Subunit; Dexamethasone; Dietary Supplements; Genistein; Glucocorticoids; Lycopene; Methylprednisolone; Osteoblasts; Osteogenesis; Osteoporosis | 2022 |